Introduction The Interim Canada Dental Benefit (CDB), introduced in 2022, provided financial assistance to families with children < 12 years. This study analyzed data from the Canada Revenue Agency (CRA) during the program’s entirety.

Methods Data were accessed from the CRA for applicants and covered both the first (October 1, 2022–June 30, 2023) and second (July 1, 2023–June 30, 2024) periods. Rates of participation were calculated using population data from Statistics Canada. Adjusted rates were calculated based on the proportion of children without private dental insurance, and without private or public insurance.

Results Over the 21 months of the Interim CDB, 408,240 regular applications were made and $401M distributed to Canadian families. More applications were made during period 1 (P1) than period 2 (P2), but more funding distributed in P2; $197M for 204,270 applications in P1 and $203M for 203,970 applications in P2. Overall, 321,000 children received the Interim CDB in P1 and 328,040 in P2. Provinces with highest rates of child participation included Manitoba, Ontario, Nova Scotia, and Saskatchewan. The highest adjusted rates based on the proportion of children without private or public insurance were Nova Scotia (673.3/1000 P1 and 717.8/1000 P2), Northwest Territories (618.4/1000 P1 and 573.2/1000 P2), and Saskatchewan (495.1/1000 P1 and 528.3/1000 P2)

Conclusions Regions with access to care challenges had higher rates uptake of the Interim CDB when adjusting for the lack of private or public insurance. Findings from this study may help inform policy decisions and reach of the CDCP.

The authors have declared no competing interest.

This study was funded by a Canadian Institutes of Health Research Applied Public Health Chair award received by Dr. Robert Schroth.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes